Q3 2025 Earnings Forecast for argenx SE Issued By Wedbush (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Wedbush boosted their Q3 2025 EPS estimates for shares of argenx in a report released on Tuesday, March 26th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $0.64 per share for the quarter, up from their prior forecast of $0.63. The consensus estimate for argenx’s current full-year earnings is ($2.07) per share. Wedbush also issued estimates for argenx’s FY2025 earnings at $1.65 EPS.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). The firm had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same period in the previous year, the firm earned ($0.70) earnings per share.

A number of other analysts have also weighed in on ARGX. William Blair lowered shares of argenx from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Raymond James reduced their price target on shares of argenx from $580.00 to $520.00 and set a “strong-buy” rating for the company in a research note on Thursday, December 21st. JPMorgan Chase & Co. reduced their price target on shares of argenx from $615.00 to $560.00 and set an “overweight” rating for the company in a research note on Tuesday, December 5th. JMP Securities reiterated a “market outperform” rating and issued a $471.00 target price on shares of argenx in a report on Friday, March 22nd. Finally, Scotiabank boosted their target price on shares of argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $530.74.

argenx Trading Down 1.2 %

Shares of NASDAQ:ARGX opened at $393.72 on Wednesday. The company has a 50 day moving average of $387.95 and a 200-day moving average of $434.94. The firm has a market cap of $23.35 billion, a P/E ratio of -76.60 and a beta of 0.65. argenx has a twelve month low of $327.73 and a twelve month high of $550.76.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Nkcfo LLC grew its position in argenx by 22.1% in the third quarter. Nkcfo LLC now owns 116 shares of the company’s stock worth $57,000 after acquiring an additional 21 shares in the last quarter. Genus Capital Management Inc. grew its position in argenx by 1.6% in the third quarter. Genus Capital Management Inc. now owns 1,605 shares of the company’s stock worth $789,000 after acquiring an additional 25 shares in the last quarter. Creative Planning grew its position in argenx by 3.0% in the fourth quarter. Creative Planning now owns 1,006 shares of the company’s stock worth $381,000 after acquiring an additional 29 shares in the last quarter. Snowden Capital Advisors LLC grew its position in argenx by 1.9% in the first quarter. Snowden Capital Advisors LLC now owns 1,920 shares of the company’s stock worth $715,000 after acquiring an additional 35 shares in the last quarter. Finally, Wahed Invest LLC grew its position in argenx by 9.6% in the fourth quarter. Wahed Invest LLC now owns 457 shares of the company’s stock worth $174,000 after acquiring an additional 40 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.